These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11815521)

  • 21. Pioglitazone-associated fulminant hepatic failure.
    Chase MP; Yarze JC
    Am J Gastroenterol; 2002 Feb; 97(2):502-3. PubMed ID: 11866308
    [No Abstract]   [Full Text] [Related]  

  • 22. Pioglitazone.
    Lawrence JM; Reckless JP
    Int J Clin Pract; 2000 Nov; 54(9):614-8. PubMed ID: 11220991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Thiazolidinediones in type 2 diabetes].
    Baum U
    Med Monatsschr Pharm; 2000 Jul; 23(7):210-3. PubMed ID: 10941251
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacokinetics and clinical efficacy of pioglitazone.
    Hanefeld M
    Int J Clin Pract Suppl; 2001 Sep; (121):19-25. PubMed ID: 11594240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes.
    Nakamura T; Ushiyama C; Osada S; Shimada N; Ebihara I; Koide H
    Ren Fail; 2001 Nov; 23(6):863-4. PubMed ID: 11777327
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
    Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S;
    Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rosiglitazone and type 2 diabetes mellitus.
    Bragg T
    Lancet; 2001 May; 357(9266):1451. PubMed ID: 11360960
    [No Abstract]   [Full Text] [Related]  

  • 29. Unraveling the mechanism of action of thiazolidinediones.
    Kahn CR; Chen L; Cohen SE
    J Clin Invest; 2000 Dec; 106(11):1305-7. PubMed ID: 11104782
    [No Abstract]   [Full Text] [Related]  

  • 30. [The efficacy and safety of pioglitazone hydrochloride in combination with sulphonylureas and metfomin in the treatment of type 2 diabetes mellitus a 12-week randomized multi-centres placebo-controlled parallel study].
    Pan C; Gao Y; Gao X; Li G; Luo B; Shi H; Tian H; Jia P; Lin H; Xing X; Zhao Y; Zhou L
    Zhonghua Nei Ke Za Zhi; 2002 Jun; 41(6):388-92. PubMed ID: 12137601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New drug overview. Pioglitazone hydrochloride.
    Am J Health Syst Pharm; 2000 Jan; 57(2):124-5. PubMed ID: 10688239
    [No Abstract]   [Full Text] [Related]  

  • 32. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study.
    Takagi T; Yamamuro A; Tamita K; Yamabe K; Katayama M; Mizoguchi S; Ibuki M; Tani T; Tanabe K; Nagai K; Shiratori K; Morioka S; Yoshikawa J
    Am Heart J; 2003 Aug; 146(2):E5. PubMed ID: 12891212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using thiazolidinediones: rosiglitazone and pioglitazone in clinical practice.
    Peters AL
    Am J Manag Care; 2001 Apr; 7(3 Suppl):S87-95; quiz S96-7. PubMed ID: 11310177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Thiazolidinediones].
    Scheen AJ; Paquot N; Letiexhe MR; Lefèbvre PJ
    Journ Annu Diabetol Hotel Dieu; 1999; ():213-29. PubMed ID: 10732419
    [No Abstract]   [Full Text] [Related]  

  • 35. Rosiglitazone approved for treatment of type 2 diabetes.
    Miller JL
    Am J Health Syst Pharm; 1999 Jul; 56(13):1292, 1294. PubMed ID: 10683120
    [No Abstract]   [Full Text] [Related]  

  • 36. Possible vascular-protective effects of antidiabetic agents such as the thiazolidinediones (TZDs).
    Goldstein BJ
    Clin Ther; 2002 Aug; 24(8):1358-60; author reply 1360-2. PubMed ID: 12240785
    [No Abstract]   [Full Text] [Related]  

  • 37. Thiazolidinediones in diabetes: current status and future outlook.
    Camp HS
    Curr Opin Investig Drugs; 2003 Apr; 4(4):406-11. PubMed ID: 12808879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Troglitazone: a new class of oral antihyperglycemic for the treatment of type II diabetes.
    Teter ML
    Nurse Pract; 1997 Jul; 22(7):119-21. PubMed ID: 9253019
    [No Abstract]   [Full Text] [Related]  

  • 39. Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats.
    Ishida H; Kato S; Nishimura M; Mizuno N; Fujimoto S; Mukai E; Kajikawa M; Yamada Y; Odaka H; Ikeda H; Seino Y
    Horm Metab Res; 1998 Nov; 30(11):673-8. PubMed ID: 9918384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.
    Miyazaki Y; Matsuda M; DeFronzo RA
    Diabetes Care; 2002 Mar; 25(3):517-23. PubMed ID: 11874940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.